SCHEMBL284982

SCHEMBL284982

[CH]1Cc2ccccc2SS1

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
RYR2 Q92736 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4862184 0.77 RYR2 (0.31) RYR2
SCHEMBL9118593 0.77 TSHR (0.33) RYR2TSHR
SCHEMBL7687194 0.67
SCHEMBL654620 0.67
SCHEMBL450053 0.65
SCHEMBL3074985 0.64 ALDH1A1 (0.37) RYR2KDM4EALDH1A1HPGD
SCHEMBL28923936 0.63 ALDH1A1 (0.34) RYR2KDM4EALDH1A1HPGDTSHR
SCHEMBL10580638 0.63 ALDH1A1 (0.34) RYR2KDM4EALDH1A1HPGDTSHR
SCHEMBL3258469 0.62
SCHEMBL9149 0.62 RYR2 (0.36) RYR2KDM4EALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3245198-B1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS NOVARTIS AG (CH) 2020-03-11 EP claimed
US-10065943-B2 Pyrrolidine derivatives as angiotensin II type 2 antagonists NOVARTIS AG (CH) 2018-09-04 US claimed
US-20170369473-A1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS SPINIFEX PHARMACEUTICALS PTY LTD (AU) 2017-12-28 US claimed
EP-3245198-A1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS Novartis AG (CH) 2017-11-22 EP claimed
WO-2016113668-A1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS NOVARTIS AG (CH) 2016-07-21 WO claimed
EP-0790983-A1 PESTICIDAL PYRIDINE THIOAMIDES Novartis AG (CH) 1997-08-27 EP claimed
WO-1996014301-A1 PESTICIDAL PYRIDINE THIOAMIDES NOVARTIS AG (CH) 1996-05-17 WO claimed
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2024-07-16 US disclosed
EP-4380920-A1 INHIBITORS FOR CORONAVIRUSES Cocrystal Pharma, Inc. (US) 2024-06-12 EP disclosed
CN-118103351-A Coronavirus inhibitors 共晶制药公司 2024-05-28 CN disclosed
CN-113286793-B Inhibitors of influenza virus replication of pyrrolopyrazines and pyridotriazines 共结晶制药公司 2024-04-05 CN disclosed
CN-112638477-B Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication 共晶制药公司 2024-01-26 CN disclosed
CN-112574191-B Isoxazole heterocyclic compound and application thereof 南京圣和药业股份有限公司 2024-01-23 CN disclosed
EP-1334973-A1 PREVENTIVE OR THERAPEUTIC MEDICINES FOR DIABETES CONTAINING FUSED-HETEROCYCLE COMPOUNDS OR THEIR SALTS ISHIHARA SANGYO KAISHA, LTD. (JP) 2003-08-13 EP disclosed
US-6596863-B2 Matrix metalloproteinase inhibitor is useful as an anticancer agent, angiogenesis inhibitor, a tumor cell infiltration inhibitor or a tumor metastasis inhibitor; inflammatory diseases, osteoarthritis, rheumatoid arthritis ISHIHARA SANGYO KAISHA, LTD. (JP) 2003-07-22 US disclosed
US-20020198184-A1 Medical composition containing nitroetheneamine derivative or salt thereof as active constituent ISHIHARA SANGYO KAISHA LTD. (JP) 2002-12-26 US disclosed
US-6451792-B1 MATRIX METALLOPROTEASE INHIBITORS ISHIHARA SANGYO KAISHA LTD. (JP) 2002-09-17 US disclosed
EP-1116486-A1 MEDICAL COMPOSITION CONTAINING NITROETHENEAMINE DERIVATIVE OR SALT THEREOF AS ACTIVE CONSTITUENT ISHIHARA SANGYO KAISHA, LTD. (JP) 2001-07-18 EP disclosed
EP-0790983-A1 PESTICIDAL PYRIDINE THIOAMIDES Novartis AG (CH) 1997-08-27 EP disclosed
WO-1996014301-A1 PESTICIDAL PYRIDINE THIOAMIDES NOVARTIS AG (CH) 1996-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369473-A1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS AGTR2, AGTR1, AVPR2 RYR2 196/4885KDM4E 3003/4885ALDH1A1 1954/4885
US-10065943-B2 Pyrrolidine derivatives as angiotensin II type 2 antagonists AGTR2, AGTR1, ACE2 RYR2 148/4885KDM4E 3419/4885ALDH1A1 2233/4885
US-20020198184-A1 Medical composition containing nitroetheneamine derivative or salt thereof as active constituent NR3C2, NR3C1, CNR1 RYR2 1261/4885KDM4E 3681/4885ALDH1A1 1194/4885
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication PLPBP, EIF2AK2, TYMP RYR2 3444/4885KDM4E 1508/4885ALDH1A1 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.